260 related articles for article (PubMed ID: 15199074)
21. Extended dosage intervals for aminoglycosides.
Rodman DP; Maxwell AJ; McKnight JT
Am J Hosp Pharm; 1994 Aug; 51(16):2016-21. PubMed ID: 7977422
[TBL] [Abstract][Full Text] [Related]
22. A survey of extended-interval aminoglycoside dosing practices in United States adult cystic fibrosis programs.
Prescott WA
Respir Care; 2014 Sep; 59(9):1353-9. PubMed ID: 24782555
[TBL] [Abstract][Full Text] [Related]
23. An evaluation of amikacin nephrotoxicity in the hematology/oncology population.
Kiel PJ; Lo M; Stockwell D; Patel GP
Am J Ther; 2008; 15(2):131-6. PubMed ID: 18356633
[TBL] [Abstract][Full Text] [Related]
24. Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosis.
de Jager P; van Altena R
Int J Tuberc Lung Dis; 2002 Jul; 6(7):622-7. PubMed ID: 12102302
[TBL] [Abstract][Full Text] [Related]
25. Easy-to-use, accurate and flexible individualized Bayesian limited sampling method without fixed time points for ciclosporin monitoring after liver transplantation.
Langers P; Cremers SC; den Hartigh J; Rijnbeek EM; Ringers J; Lamers CB; van Hoek B
Aliment Pharmacol Ther; 2005 Mar; 21(5):549-57. PubMed ID: 15740538
[TBL] [Abstract][Full Text] [Related]
26. Once-daily aminoglycoside dosing: An update on current literature.
Stankowicz MS; Ibrahim J; Brown DL
Am J Health Syst Pharm; 2015 Aug; 72(16):1357-64. PubMed ID: 26246292
[TBL] [Abstract][Full Text] [Related]
27. Once daily aminoglycoside dosing: maintained efficacy with reduced nephrotoxicity?
Zhanel GG; Ariano RE
Ren Fail; 1992; 14(1):1-9. PubMed ID: 1561384
[TBL] [Abstract][Full Text] [Related]
28. Once-daily aminoglycoside dosing in immunocompetent adults: a meta-analysis.
Hatala R; Dinh T; Cook DJ
Ann Intern Med; 1996 Apr; 124(8):717-25. PubMed ID: 8633831
[TBL] [Abstract][Full Text] [Related]
29. Comparison of once-daily versus pharmacokinetic dosing of aminoglycosides in elderly patients.
Koo J; Tight R; Rajkumar V; Hawa Z
Am J Med; 1996 Aug; 101(2):177-83. PubMed ID: 8757358
[TBL] [Abstract][Full Text] [Related]
30. Pharmacoeconomic impact of once-daily aminoglycoside administration.
Hitt CM; Klepser ME; Nightingale CH; Quintiliani R; Nicolau DP
Pharmacotherapy; 1997; 17(4):810-4. PubMed ID: 9250562
[TBL] [Abstract][Full Text] [Related]
31. Can pharmacokinetic dosing decrease nephrotoxicity associated with aminoglycoside therapy.
Leehey DJ; Braun BI; Tholl DA; Chung LS; Gross CA; Roback JA; Lentino JR
J Am Soc Nephrol; 1993 Jul; 4(1):81-90. PubMed ID: 8400072
[TBL] [Abstract][Full Text] [Related]
32. Aminoglycosides in hemodialysis patients: is the current practice of post dialysis dosing appropriate?
O'Shea S; Duffull S; Johnson DW
Semin Dial; 2009; 22(3):225-30. PubMed ID: 19386073
[TBL] [Abstract][Full Text] [Related]
33. Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases.
Peloquin CA; Berning SE; Nitta AT; Simone PM; Goble M; Huitt GA; Iseman MD; Cook JL; Curran-Everett D
Clin Infect Dis; 2004 Jun; 38(11):1538-44. PubMed ID: 15156439
[TBL] [Abstract][Full Text] [Related]
34. Extended-interval dosing of aminoglycosides.
Blam ME; Hammer GS
Mt Sinai J Med; 1997 Nov; 64(6):386-91. PubMed ID: 9364833
[TBL] [Abstract][Full Text] [Related]
35. Aminoglycosides in intermittent hemodialysis: pharmacokinetics with individual dosing.
Dager WE; King JH
Ann Pharmacother; 2006 Jan; 40(1):9-14. PubMed ID: 16332944
[TBL] [Abstract][Full Text] [Related]
36. [Evaluation of the incidence of nephrotoxicity associated with the use of aminoglycosides in patients with extrahepatic biliary obstruction].
Márquez E; Lucena MI; Andrade RJ; González-Correa JA; Clavijo E; Lazo MD; Sánchez de la Cuesta F
Rev Clin Esp; 1992 Jun; 191(2):76-9. PubMed ID: 1502393
[TBL] [Abstract][Full Text] [Related]
37. Optimizing use of aminoglycosides in the critically ill.
Rea RS; Capitano B
Semin Respir Crit Care Med; 2007 Dec; 28(6):596-603. PubMed ID: 18095223
[TBL] [Abstract][Full Text] [Related]
38. The use of extended-interval aminoglycoside dosing strategies for the treatment of moderate-to-severe infections encountered in critically ill surgical patients.
Mueller EW; Boucher BA
Surg Infect (Larchmt); 2009 Dec; 10(6):563-70. PubMed ID: 20035611
[TBL] [Abstract][Full Text] [Related]
39. [Prevision of aminoglycoside nephrotoxicity (author's transl)].
Lucht F; Peyramond D; Robert D; Vincent P
Pathol Biol (Paris); 1982 Apr; 30(4):227-31. PubMed ID: 7045782
[TBL] [Abstract][Full Text] [Related]
40. Pharmacological considerations for the proper clinical use of aminoglycosides.
Pagkalis S; Mantadakis E; Mavros MN; Ammari C; Falagas ME
Drugs; 2011 Dec; 71(17):2277-94. PubMed ID: 22085385
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
